Cargando…
Two cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer’s disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterio...
Autores principales: | Kimura, Takemi, Takamatsu, Junichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534308/ https://www.ncbi.nlm.nih.gov/pubmed/23293526 http://dx.doi.org/10.2147/NDT.S37688 |
Ejemplares similares
-
The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease
por: Sasaki, Shoichi, et al.
Publicado: (2014) -
Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease
por: Kagawa, Yoshiyuki, et al.
Publicado: (2021) -
Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
por: Zhou, Yi, et al.
Publicado: (2023) -
Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
por: Oh, Yoon-Sang, et al.
Publicado: (2015) -
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)